Stephen KL Chia
机构: Medical Oncology, British Columbia Cancer Agency
每年引用次数
引用次数
引用: 31,786
H-指数: 78
I10-指数 : 208
出版物: 538
Patient-reported outcomes in a linguistically diverse cancer population: Addressing barriers to access.
Fatima Usman , Rebekah Rittberg , Howard John Lim , Eric Bhang
Journal of Clinical Oncology 40 ( 28_suppl) 168 -168
2022
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).
Kevin Kalinsky , William E Barlow , Harsh B Pathak , Julie R Gralow
Journal of Clinical Oncology 42 ( 16_suppl) 505 -505
2024
Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2-metastatic breast cancer with detectable ESR1 m who have not experienced disease progression on first-line therapy
François-Clément Bidard , Kevin Kalinsky , Massimo Cristofanilli , Giampaolo Bianchini
Cancer Research 82 ( 4_Supplement) OT2 -OT2
15
2022
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.
Yara Abdou , Jess R Hoag , William E Barlow , Julie R Gralow
Journal of Clinical Oncology 42 ( 16_suppl) 515 -515
2024
Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with fulvestrant (FUL)±ribociclib (RIB)
Dennis J Slamon , Patrick Neven , Stephen KL Chia , Guy Heinrich Maria Jerusalem
J Clin Oncol 39 ( 15_suppl) 1001 -1001
62
2021
Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.
Peter A Fasching , Guy Heinrich Maria Jerusalem , Xavier Pivot , Miguel Martin
Journal of Clinical Oncology 34 ( 15_suppl) TPS624 -TPS624
15
2016
Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.
Stephen KL Chia , Manuel Ruiz-Borrego , Pamela Drullinsky , Dejan Juric
Journal of Clinical Oncology 39 ( 15_suppl) 1060 -1060
7
2021
Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Emily B Jackson , Stephen KL Chia
Journal of Clinical Oncology 41 ( 24) 3976 -3983
4
2023
Alpelisib (ALP)+ endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.
Dejan Juric , Hope S Rugo , Stephen KL Chia , Florence Lerebours
Journal of Clinical Oncology 40 ( 16_suppl) 1018 -1018
2
2022
Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
Hope S Rugo , Manuel Ruiz Borrego , Stephen KL Chia , Dejan Juric
JOURNAL OF CLINICAL ONCOLOGY 37 ( 15)
2
2019
Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.
Denise A Yardley , Michael Untch , Carlos H Barrios Sr , Aditya Bardia
Journal of Clinical Oncology 42 ( 16_suppl) 512 -512
2024
Real world outcomes of 2,339 patients with early-stage triple-negative breast cancer (TNBC) treated in British Columbia.
Mairi Lucas , Stephen KL Chia , Caroline Speers , Caroline A Lohrisch
Journal of Clinical Oncology 42 ( 16_suppl) e23274 -e23274
2024
On-treatment (tx) dynamic circulating tumor DNA changes (∆ ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3).
Stephen KL Chia , Nadia Solovieff , Mukta Joshi , Seock-Ah Im
Journal of Clinical Oncology 42 ( 16_suppl) 1012 -1012
2024
Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response
Carmine Valenza , Dario Trapani , Sibylle Loibl , Stephen KL Chia
Journal of Clinical Oncology JCO. 23.01935 -JCO. 23.01935
2024
Treatment Algorithms for Hormone Receptor-Positive Advanced Breast Cancer
Stephen RD Johnston , Todd W Miller , NH Hanover , Stephen KL Chia
American Society of Clinical Oncology Educational Book 50 -50
2024
Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with hormone receptorpositive (HR plus), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.
Juric Dejan , Hope S Rugo , Stephen KL Chia , Florence Lerebours
Journal Of Clinical Oncology 40 ( 16)
2022
PIK3CA-mutated (mut) hormone receptor-positive (HR plus), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) plus aromatase inhibitor (AI): BYLieve study results.
Hope S Rugo , Florence Lerebours , Eva Ciruelos , Pamela Drullinsky
Journal Of Clinical Oncology 38 ( 15)
2020
Treat ER (+) ight: Canadian prospective observational study in post-menopausal HIR+ FIER2 (-) advanced breast cancer women-First interim analysis (IA).
Cristiano Ferrari , Nadia Califaretti , Catherine Doyle , Susan Faye Dent
JOURNAL OF CLINICAL ONCOLOGY 35
2017
Year in review for local/triple negative/cytotoxic therapy (ASCO 2011)
Stephen KL Chia
日本癌治療学会誌= The journal of Japan Society of Clinical Oncology 46 ( 3) 1172 -1175
2011
SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2-metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy
Francois-Clement Bidard , Kevin Kalinsky , Massimo Cristofanilli , Giampaolo Bianchini
CANCER RESEARCH 82 ( 4)
2022